These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11550931)

  • 21. Modeling a Poisson forest in variable elevations: a nonparametric Bayesian approach.
    Heikkinen J; Arjas E
    Biometrics; 1999 Sep; 55(3):738-45. PubMed ID: 11315001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs.
    Iyer L; Koza M; Iqbal O; Calabria R; Fareed J
    Thromb Res; 1993 Feb; 69(3):259-69. PubMed ID: 8475476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting.
    Sasaki T; Tabuchi H; Higuchi S; Ieiri I
    Pharmacogenomics; 2009 Aug; 10(8):1257-66. PubMed ID: 19663670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gamma generalized linear models for pharmacokinetic data.
    Salway R; Wakefield J
    Biometrics; 2008 Jun; 64(2):620-6. PubMed ID: 17888039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of some control strategies for three-compartment PK/PD models.
    Hu C; Lovejoy WS; Shafer SL
    J Pharmacokinet Biopharm; 1994 Dec; 22(6):525-50. PubMed ID: 7473080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
    Jordan P; Brunschwig H; Luedin E
    Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic-pharmacodynamic models for categorical toxicity data.
    Diack C; Bois FY
    Regul Toxicol Pharmacol; 2005 Feb; 41(1):55-65. PubMed ID: 15649827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
    Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
    J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design.
    Reddy MB; Yang KH; Rao G; Rayner CR; Nie J; Pamulapati C; Marathe BM; Forrest A; Govorkova EA
    PLoS One; 2015; 10(10):e0138069. PubMed ID: 26460484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model.
    Lyons MA; Lenaerts AJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):375-89. PubMed ID: 26026426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia.
    Fish DN; Kiser TH
    Pharmacotherapy; 2013 Oct; 33(10):1022-34. PubMed ID: 23744833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid.
    Delavenne X; Laporte S; Demasles S; Mallouk N; Basset T; Tod M; Girard P; Mismetti P
    Fundam Clin Pharmacol; 2009 Feb; 23(1):127-35. PubMed ID: 19267776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A hierarchical Bayesian approach for combining pharmacokinetic/pharmacodynamic modeling and Phase IIa trial design in orphan drugs: Treating adrenoleukodystrophy with Lorenzo's oil.
    Basu C; Ahmed MA; Kartha RV; Brundage RC; Raymond GV; Cloyd JC; Carlin BP
    J Biopharm Stat; 2016; 26(6):1025-1039. PubMed ID: 27547896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.
    Gumbleton M; Oie S; Verotta D
    Br J Clin Pharmacol; 1994 Nov; 38(5):389-400. PubMed ID: 7893578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Desirudin dosing and monitoring in moderate renal impairment.
    Nafziger AN; Bertino JS
    J Clin Pharmacol; 2010 Jun; 50(6):614-22. PubMed ID: 19915180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bayesian nonparametric population models: formulation and comparison with likelihood approaches.
    Wakefield J; Walker S
    J Pharmacokinet Biopharm; 1997 Apr; 25(2):235-53. PubMed ID: 9408861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bayesian dynamic modeling of latent trait distributions.
    Dunson DB
    Biostatistics; 2006 Oct; 7(4):551-68. PubMed ID: 16488893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.